AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 619934 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled release tablet containing 300 mg of papaverine hydrochloride
Number of subjects: 0
Study 619934 — intervention group
Group type: COMPARATOR
Intervention: Capsule containing 300 mg of papaverine hydrochloride
Number of subjects: 0
Study 30531418 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyo Press Power Quotient (3PQ) test using a horizontal leg press equipped with a force plate
Number of subjects: 30
Study 30531418 — intervention group
Group type: EXPERIMENTAL
Intervention: 1RM strength testing for 1 and 2 legs and countermovement vertical jump
Number of subjects: 30
Study 30531418 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-leg jump tests at 30, 40, 50, and 60% of 1RM for 20 and 30 seconds
Number of subjects: 30
Study 29464487 — intervention group
Group type: EXPERIMENTAL
Intervention: Myopic monovision group (dominant eye -2.75D, nondominant eye -1.75D)
Number of subjects: 60
Study 29464487 — intervention group
Group type: EXPERIMENTAL
Intervention: Myopic monovision group
Number of subjects: 60
Study 29464487 — intervention group
Group type: COMPARATOR
Intervention: Non-monovision group (bilateral -2.75D)
Number of subjects: 60
Study 29464487 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 26744025 — intervention group
Group type: EXPERIMENTAL
Intervention: liraglutide 3.0 mg
Number of subjects: 5325
Study 26744025 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 5325
Study 23130938 — intervention group
Group type: EXPERIMENTAL
Intervention: SOLITAIRE™ Flow Restoration device
Number of subjects: 0
Study 23130938 — intervention group
Group type: COMPARATOR
Intervention: MERCI Retrieval System®
Number of subjects: 0
Study 23173830 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem Solving Therapy (PST)
Number of subjects: 0
Study 23173830 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 0
Study 23173830 — intervention group
Group type: COMPARATOR
Intervention: Enhanced treatment-as-usual (E-TAU)
Number of subjects: 0
Study 23173830 — intervention group
Group type: EXPERIMENTAL
Intervention: PST and CBT
Number of subjects: 0
Study 20152559 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stent (ZES)
Number of subjects: 1548
Study 20152559 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 1548
Study 17722957 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-week cycles of intravenous (IV) docetaxel plus cisplatin and fluorouracil (5-fluorouracil)
Number of subjects: 445
Study 17722957 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin plus IV fluorouracil (4-week cycles)
Number of subjects: 445
Study 16252573 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine 3‐6 mg twice daily for 20 weeks
Number of subjects: 38
Study 16252573 — intervention group
Group type: COMPARATOR
Intervention: Control group (no rivastigmine)
Number of subjects: 38
Study 11697709 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (0.3 g/kg in a 4-week cycle until the 28th to 32nd week of gestation), aspirin (100 mg/d), and certoparin (3,000 anti-Xa U/d)
Number of subjects: 66
Study 11697709 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (aspirin and low‐molecular‐weight heparin)
Number of subjects: 66
Study 9918642 — intervention group
Group type: EXPERIMENTAL
Intervention: Bionators
Number of subjects: 168
Study 9918642 — intervention group
Group type: EXPERIMENTAL
Intervention: Headgears
Number of subjects: 168
Study 9918642 — intervention group
Group type: COMPARATOR
Intervention: Both Bionators and Headgears
Number of subjects: 168
Study 7998586 — intervention group
Group type: EXPERIMENTAL
Intervention: rilmenidine 1-2 mg/day (n = 46)
Number of subjects: 88
Study 7998586 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCZ) 25-50 mg/day (n = 42)
Number of subjects: 88
Study 3056208 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ceftriaxone (1%) at induction of anaesthesia
Number of subjects: 243
Study 3056208 — intervention group
Group type: COMPARATOR
Intervention: Povidone iodine sprayed into the wound at the completion of surgery
Number of subjects: 243
Study 29893942 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 108
Study 29893942 — intervention group
Group type: COMPARATOR
Intervention: Sham electroacupuncture
Number of subjects: 108
Study 29893942 — intervention group
Group type: COMPARATOR
Intervention: Education alone
Number of subjects: 108
Study 29893942 — intervention group
Group type: COMPARATOR
Intervention: Education alone (after electroacupuncture during follow-up)
Number of subjects: 108
Study 28430748 — intervention group
Group type: EXPERIMENTAL
Intervention: Vero cell‐derived inactivated JE virus vaccine (IXIARO), 0.25 mL for <3 years and 0.5 mL for ≥3 years, administered 28 days apart
Number of subjects: 496
Study 25881753 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomaglumetad methionil 400 mg
Number of subjects: 86
Study 25881753 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 25881753 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg
Number of subjects: 86
Study 22843041 — intervention group
Group type: EXPERIMENTAL
Intervention: Sand training surface
Number of subjects: 10
Study 22843041 — intervention group
Group type: COMPARATOR
Intervention: Grass training surface
Number of subjects: 10
Study 21515164 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance-based payment (P4P) for health-care providers
Number of subjects: 2158
Study 21515164 — intervention group
Group type: COMPARATOR
Intervention: Traditional input-based funding
Number of subjects: 2158
Study 20027348 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaferon (pediatric formulation) as a component of complex therapy
Number of subjects: 0
Study 16495392 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine 1500 mg daily
Number of subjects: 1583
Study 16495392 — intervention group
Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate 1200 mg daily
Number of subjects: 1583
Study 16495392 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined glucosamine and chondroitin sulfate
Number of subjects: 1583
Study 16495392 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib 200 mg daily
Number of subjects: 1583
Study 16495392 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (glucosamine and chondroitin sulfate) in moderate-to-severe pain
Number of subjects: 1583
Study 15527670 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 401
Study 15527670 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 401
Study 11134125 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol therapy (transdermal or oral)
Number of subjects: 27
Study 11134125 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 27
Study 9481970 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0MAC with block analgesia
Number of subjects: 28
Study 9481970 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.3MAC with block analgesia
Number of subjects: 28
Study 9481970 — intervention group
Group type: COMPARATOR
Intervention: 1.3MAC without block analgesia
Number of subjects: 28
Study 9481970 — intervention group
Group type: COMPARATOR
Intervention: 1.6MAC without block analgesia
Number of subjects: 28
Study 7885579 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking with hand movements
Number of subjects: 6
Study 7885579 — intervention group
Group type: COMPARATOR
Intervention: Walking with no hand movements
Number of subjects: 6
Study 7885579 — intervention group
Group type: COMPARATOR
Intervention: Age-matched control patients
Number of subjects: 6
Study 3351823 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefonicid (1 g preoperative dose)
Number of subjects: 100
Study 3351823 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin (2 g preoperative and postoperative for a total of four doses)
Number of subjects: 100
Study 29458053 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole grain diet (WG diet)
Number of subjects: 80
Study 29458053 — intervention group
Group type: COMPARATOR
Intervention: Refined grain diet (RG diet)
Number of subjects: 80
Study 27203820 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low calorie diet
Number of subjects: 64
Study 25784723 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (n=28)
Number of subjects: 48
Study 25784723 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=20)
Number of subjects: 48
Study 23183881 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir (LPV)
Number of subjects: 0
Study 23183881 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir (ABC)
Number of subjects: 0
Study 23183881 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine (NVP)
Number of subjects: 0
Study 23183881 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine (3TC)
Number of subjects: 0
Study 23183881 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV)
Number of subjects: 0
Study 21122270 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab treatment for 6 months
Number of subjects: 30
Study 21122270 — intervention group
Group type: COMPARATOR
Intervention: Control group (age- and weight-matched men)
Number of subjects: 30
Study 18230018 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothetical cardiac risk information with a focus on relative differences
Number of subjects: 0
Study 18230018 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothetical cardiac risk information with a focus on absolute differences
Number of subjects: 0
Study 16732903 — intervention group
Group type: EXPERIMENTAL
Intervention: PegIntron (1.0 microg/kg body weight, SC, once a week)
Number of subjects: 230
Study 16732903 — intervention group
Group type: COMPARATOR
Intervention: Intron A (3 MIU SC, three times a week)
Number of subjects: 230
Study 16732903 — intervention group
Group type: EXPERIMENTAL
Intervention: PegIntron
Number of subjects: 230
Study 16732903 — intervention group
Group type: COMPARATOR
Intervention: Intron A
Number of subjects: 230
Study 12079904 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant DNA hepatitis B vaccine (3 doses: 2nd and 3rd doses at 1 and 6 months)
Number of subjects: 44
Study 12079904 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant DNA hepatitis B vaccine
Number of subjects: 44
Study 12079904 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vaccination)
Number of subjects: 44
Study 9460778 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (four days/week; 30-40 minutes/session)
Number of subjects: 24
Study 9460778 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 24
Study 9460778 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise with physician recommendation
Number of subjects: 24
Study 9460778 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 24
Study 8589769 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexfenfluramine
Number of subjects: 50
Study 8589769 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 2162877 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazide diuretic (Moduretic; Merck Sharp & Dohme)
Number of subjects: 2630
Study 2162877 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocking agent (atenolol)
Number of subjects: 2630
Study 2162877 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 2630
Study 418433 — intervention group
Group type: EXPERIMENTAL
Intervention: PRL-8-53
Number of subjects: 0
Study 418433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6177804 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (IFN) titer greater than 10 units in acute-phase sera
Number of subjects: 57
Study 6177804 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiviral activity in acute-phase sera
Number of subjects: 57
Study 6177804 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent-phase sera
Number of subjects: 57
Study 31517756 — intervention group
Group type: EXPERIMENTAL
Intervention: MINDBODYSTRONG Program
Number of subjects: 89
Study 31517756 — intervention group
Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 89
Study 29110922 — intervention group
Group type: EXPERIMENTAL
Intervention: Trifluridine/tipiracil + Best Supportive Care (BSC)
Number of subjects: 0
Study 29110922 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib
Number of subjects: 0
Study 29110922 — intervention group
Group type: COMPARATOR
Intervention: Best Supportive Care (BSC) alone
Number of subjects: 0
Study 27007989 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer
Number of subjects: 50
Study 27007989 — intervention group
Group type: COMPARATOR
Intervention: Calcium Carbonate
Number of subjects: 50
Study 24726204 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Pharmacist‐Led Guidance Teams (CPGTs)
Number of subjects: 542
Study 24726204 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 542
Study 23225555 — intervention group
Group type: EXPERIMENTAL
Intervention: Transanal real-time elastography (RTE)
Number of subjects: 90
Study 23225555 — intervention group
Group type: COMPARATOR
Intervention: Conventional B-mode/color Doppler EUS
Number of subjects: 90
Study 21139110 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated care (IC)
Number of subjects: 943
Study 21139110 — intervention group
Group type: COMPARATOR
Intervention: Referral to Veterans Affairs smoking cessation clinics (SCC)
Number of subjects: 943
Study 17650171 — intervention group
Group type: COMPARATOR
Intervention: Rinsing with water
Number of subjects: 36
Study 17650171 — intervention group
Group type: EXPERIMENTAL
Intervention: Soaking in an alkaline peroxide solution (Bonyplus)
Number of subjects: 36
Study 17650171 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushing with dentifrice (Dentu‐Creme) and soft Johnson and Johnson's toothbrush
Number of subjects: 36
Study 17650171 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of soaking and brushing (methods 2 and 3)
Number of subjects: 36
Study 17650171 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushing with dentifrice (Dentu‐Creme) and soft Oral B toothbrush
Number of subjects: 36
Study 17650171 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of soaking and brushing (methods 2 and 5)
Number of subjects: 36
Study 16301884 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (1 mg/kg IV) + remifentanil (1 microg/kg)
Number of subjects: 21
Study 16301884 — intervention group
Group type: COMPARATOR
Intervention: Propofol (1 mg/kg IV)
Number of subjects: 21
Study 11896441 — intervention group
Group type: EXPERIMENTAL
Intervention: dl1520 gene therapy
Number of subjects: 10
Study 11896441 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous ethanol injection (control group)
Number of subjects: 10
Study 9790607 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment-driven algorithm for treatment of pediatric status asthmaticus
Number of subjects: 201
Study 9790607 — intervention group
Group type: COMPARATOR
Intervention: Unstructured standard treatment
Number of subjects: 201
Study 7631682 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 20
Study 7631682 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulindac
Number of subjects: 20
Study 2533582 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg s.I.)
Number of subjects: 8
Study 2533582 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 342627 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated influenza virus vaccine (200 CCA units of influenza A/New Jersey/76 and 200 CCA units of influenza A/Victoria/75)
Number of subjects: 88
Study 342627 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 342627 — intervention group
Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 88
Study 342627 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated influenza virus vaccine
Number of subjects: 88
Study 31096775 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg vericiguat
Number of subjects: 735
Study 31096775 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg vericiguat
Number of subjects: 735
Study 31096775 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 735
Study 27933425 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 211
Study 27933425 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 211
Study 27120065 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylspiramycin plus garlicin
Number of subjects: 151
Study 27120065 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylspiramycin only
Number of subjects: 151
Study 27120065 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlicin only
Number of subjects: 151
Study 27120065 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 151
Study 23616126 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS - CGN
Number of subjects: 68
Study 23616126 — intervention group
Group type: COMPARATOR
Intervention: EUS - CPN
Number of subjects: 68
Study 22121861 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of antipsychotic treatment for at least 6 months
Number of subjects: 20
Study 22121861 — intervention group
Group type: COMPARATOR
Intervention: Gradual withdrawal of antipsychotic treatment
Number of subjects: 20
Study 19967647 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer
Number of subjects: 360
Study 19967647 — intervention group
Group type: COMPARATOR
Intervention: Calcium-binder phosphate
Number of subjects: 360
Study 17182194 — intervention group
Group type: EXPERIMENTAL
Intervention: Drinker Inventory of Consequences (DrInC)
Number of subjects: 1382
Study 17182194 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-item Short Inventory of Problems (SIP)
Number of subjects: 1382
Study 15094539 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar fusion
Number of subjects: 284
Study 15094539 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical treatment
Number of subjects: 284
Study 12473554 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant vitamin C (25 mg/min; IA)
Number of subjects: 14
Study 12473554 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelium‐bound ecSOD activity
Number of subjects: 14
Study 12473554 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelium‐bound xanthine‐oxidase activity
Number of subjects: 14
Study 12473554 — intervention group
Group type: COMPARATOR
Intervention: Vitamin C
Number of subjects: 14
Study 9809262 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver-based intervention program (12-week intervention with lectures and on-site consultations)
Number of subjects: 35
Study 9809262 — intervention group
Group type: COMPARATOR
Intervention: Day care alone
Number of subjects: 35
Study 7707809 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms TRH intravenously every 12 h up to a maximum of four doses
Number of subjects: 1234
Study 7707809 — intervention group
Group type: COMPARATOR
Intervention: Placebo intravenously every 12 h up to a maximum of four doses
Number of subjects: 1234
Study 2269171 — intervention group
Group type: EXPERIMENTAL
Intervention: HA granules with ePTFE membrane
Number of subjects: 4
Study 2269171 — intervention group
Group type: EXPERIMENTAL
Intervention: ePTFE membrane alone
Number of subjects: 4
Study 2269171 — intervention group
Group type: COMPARATOR
Intervention: HA granules alone (Control)
Number of subjects: 4
Study 628535 — intervention group
Group type: EXPERIMENTAL
Intervention: Ypsilon‐Y intrauterine device (IUD)
Number of subjects: 347
Study 628535 — intervention group
Group type: COMPARATOR
Intervention: Lippes loop D
Number of subjects: 347
Study 30945510 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium alginate
Number of subjects: 0
Study 30945510 — intervention group
Group type: COMPARATOR
Intervention: Proton pump inhibitors (PPI)
Number of subjects: 0
Study 29957285 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective upper airway stimulation (sUAS)
Number of subjects: 62
Study 29957285 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients younger than 65 years with matched AHI and BMI)
Number of subjects: 62
Study 26574625 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/day for 8 weeks
Number of subjects: 64
Study 26574625 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-treated SLE patients)
Number of subjects: 64
Study 23873857 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete percutaneous approach (pre-closure technique)
Number of subjects: 274
Study 23873857 — intervention group
Group type: COMPARATOR
Intervention: Surgical cut-down/repair
Number of subjects: 274
Study 22006502 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical silver sulfadiazine (SSD) cream 1%, three times a day, 3 days a week, for 5 weeks during radiotherapy and one week thereafter
Number of subjects: 102
Study 22006502 — intervention group
Group type: COMPARATOR
Intervention: General skin care (Control)
Number of subjects: 102
Study 19013762 — intervention group
Group type: EXPERIMENTAL
Intervention: Active microbicide
Number of subjects: 132
Study 19013762 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 19013762 — intervention group
Group type: EXPERIMENTAL
Intervention: ACASI
Number of subjects: 132
Study 17203297 — intervention group
Group type: EXPERIMENTAL
Intervention: Radon (plus CO2) baths
Number of subjects: 134
Study 17203297 — intervention group
Group type: COMPARATOR
Intervention: Artificial CO2 baths
Number of subjects: 134
Study 15465502 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy
Number of subjects: 0
Study 15465502 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidronate
Number of subjects: 0
Study 15465502 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin
Number of subjects: 0
Study 15465502 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfacalcidol
Number of subjects: 0
Study 15465502 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K
Number of subjects: 0
Study 11400999 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan depletion (TD)
Number of subjects: 10